TGFB1 and diffuse large B-cell lymphoma: Additionally, efforts should focus on both molecular targeting approaches—including monoclonal antibodies and small‐molecule inhibitors, as well as complementary strategies such as miRNA agomirs—and delivery strategies (e.g., nanomaterial‐based systems) to achieve precise modulation of the miR‐19a‐3p/BAMBI/TGF‐β1 axis in the HBV+ DLBCL.